LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced today that it has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration, conducted through its Venezuelan operating subsidiary LATAMEDAI VE, aims to design, develop, test, and evaluate customized technology intended to support workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis.
The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. LataMed AI and DROGUERIAS LALA C.A. will begin identifying specific workflows to be addressed, defining technical and operational requirements, and establishing a phased development and testing process. The parties also intend to establish appropriate confidentiality, information-security, data-management, and access-control procedures.
The collaboration is significant because it represents a strategic move by LataMed AI to expand its artificial intelligence capabilities beyond patient-facing telemedicine services into enterprise pharmaceutical and laboratory applications. Management believes this initiative aligns with the Company's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, institutions, and other participants in the healthcare ecosystem. If successfully developed and implemented, the resulting technology could provide a framework adaptable for other pharmaceutical, laboratory, and healthcare organizations in Venezuela and elsewhere in Latin America, subject to separate agreements and regulatory requirements.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
The parties will evaluate whether the proposed technology can assist qualified personnel with the organization and review of information associated with pharmaceutical formulas, laboratory results, quality standards, testing procedures, and applicable approval processes. However, any such functionality is designed as a decision-support and workflow-management resource and would not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. All pharmaceutical, scientific, laboratory, and quality-control determinations will remain the responsibility of qualified professionals and regulatory authorities. The technology will not replace independent professional judgment.
The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation schedule, commercial deployment, cost reduction, scientific or regulatory outcomes, revenue, or expansion. The parties will also evaluate ownership, licensing, and intellectual property terms. For additional information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
